Endocrinology and Diabetes Management: Industry Report

Summary

Endocrinology and diabetes management covers the diagnosis, treatment and monitoring of diabetes and related endocrine conditions. The latest available data show a large and growing patient population: about 589 million adults aged 20 to 79 were living with diabetes ², and a forecast of about 853 million is projected ². About 43% of adults with diabetes are undiagnosed ³, and more than half of adults aged 30 and over with diabetes were not taking medication ⁵. In the United States, specialist supply is a documented concern. An estimated 8,000 endocrinologists are active ¹³, and a shortage of about 2,700 is projected without intervention ¹¹. The pack contains no verified market-size, pricing, provider-type quality or digital adoption data. The main risks are specialist shortage, insulin access gaps and weak comparable evidence. The outlook is that demand growth will outpace specialist capacity unless care is delegated, diagnosis improves and access barriers are addressed.

Key findings

1. 1

   Diabetes demand is large and forecast to rise

   About 589 million adults aged 20 to 79 were living with diabetes, with a projected 853 million, an increase of 46%. Global prevalence is estimated at 11.11% of adults, projected to reach about 12.96%.

   Confidence: High
2. 2

   Diagnosis and treatment gaps are substantial

   An estimated 43% of adults with diabetes, about 252 million people, are undiagnosed. More than half of adults aged 30 and over with diabetes were not taking medication, and one in two people needing insulin for type 2 diabetes does not receive it.

   Confidence: High
3. 3

   Insulin access is constrained by price, supply and health system capacity

   WHO identifies high prices, low human insulin availability, few producers and weak health systems as main access barriers. Treatment coverage is lowest in low- and middle-income countries.

   Confidence: High
4. 4

   The United States faces a specialist workforce concern with conflicting counts

   Estimates of active endocrinologists range from about 5,700 to 8,000 in the pack. A shortage of about 2,700 is projected without intervention, and many fellowship positions are not filling despite a 78% increase over about 15 years.

   Confidence: Medium
5. 5

   Pediatric and access constraints are reported but not quantified at market level

   Several states have fewer than 5 pediatric endocrinologists each, and 58.8% of primary care physicians identify a local shortage. Patients often face long waits for an initial endocrinologist visit, but no verified waiting-time figures were retrieved.

   Confidence: Medium
6. 6

   Type 1 diabetes data are incomplete

   About 9.5 million people were living with clinically diagnosed type 1 diabetes, but only 83 of 202 countries assessed had incidence data available.

   Confidence: High

1Industry definition and scope

This report covers endocrinology and diabetes management: the clinical and service activity that diagnoses and treats diabetes, monitors glycemic control and manages related endocrine conditions. The segment includes specialist endocrinology practice, primary care diabetes management, pediatric endocrinology, insulin and related therapy supply, and the workforce that delivers these services.

The geographic scope is global, with United States workforce and access evidence used as a national example. The reporting period is the latest available data in the pack. Figures are not fully interchangeable because the sources use different age bases: IDF prevalence refers to adults aged 20 to 79 ¹, while WHO refers to adults aged 18 and older ⁵. Type 1 diabetes estimates come from a separate IDF group ⁴.

Excluded are the wider healthcare sector and non-diabetes endocrine conditions, except where workforce sources combine them, such as thyroid disease in US endocrinologist estimates ¹⁰. This report describes aggregate market and population evidence. It is not individual medical advice.

2Market size, structure and value chain

The pack contains no verified market-size, revenue or spend figure for endocrinology and diabetes services or products. This report therefore cannot state market value or growth in currency terms. Demand volumes are used as a proxy for scale only, and they should not be read as revenue.

The table below sets out the demand indicators in the pack. Projected figures are forecasts from IDF modeling and are not observed counts. The WHO figure uses a different age base and is shown for comparison only.

The value chain in the pack runs from patients and families through primary care and specialist endocrinologists, including the fellowship pipeline that shapes future supply ¹¹, to insulin manufacturers and health systems. WHO notes that few producers supply human insulin ⁶. Revenue models, payer mix and provider economics were not retrieved.

Demand and supply are geographically separated. Four in five adults with diabetes live in low and middle-income countries ³, while the specialist workforce evidence in the pack relates mainly to the United States ¹³. A vendor blog estimates that 150 million people depend on insulin worldwide ¹⁴. This is a secondary vendor claim and was not used as a verified market figure.

• Adults living with diabetes 589million adults aged 20 to 79 Observed Global, Latest available data [2]

Table values are copied from the pack. Rows use different age bases and definitions, so they are compared descriptively only.

3Customers, demand and adoption

The main end users are people living with diabetes, their families (particularly for children), primary care clinicians and the health systems that finance care. Demand is driven by rising prevalence ¹², by undiagnosed disease ³ and by untreated disease, since more than half of adults aged 30 and over with diabetes were not taking medication ⁵.

Barriers to demand conversion include insulin pricing, limited human insulin availability and weak health systems ⁶. WHO also notes that access to insulin and associated devices remains limited in many countries ⁷. Purchasing criteria, patient preferences and satisfaction data were not present in the pack, so this report cannot rank what patients value most.

Access to specialist care is a documented constraint. Patients often face long waits for an initial endocrinologist visit ⁸. Pediatric endocrinology ranks third in wait times, and 58.8% of primary care physicians identify a local shortage ¹². Verified waiting-time figures were not retrieved.

Expectations are changing in the sense that primary care is taking on more diabetes specialist roles where specialists are scarce ⁹. The pack has no verified data on adoption of digital or telemedicine diabetes services, so changing patient expectations for digital care cannot be measured here.

• Adults aged 30 and over with diabetes not taking medication 59percent Observed Global, Latest available data [5]
• Adults with diabetes who are undiagnosed 43percent Observed Global, Latest available data [3]

4Competitive landscape and key players

The pack does not allow a fair comparison of public, private and community providers. No spend, volume, quality or outcome data by provider type were retrieved. Any ranking of provider performance would therefore be unsupported.

Provider types can still be described qualitatively. Specialist endocrinology practices are concentrated in the United States, where the workforce is limited ¹³. Primary care providers in low and middle-income countries increasingly take on diabetes specialist roles because of specialist shortages ⁹. Community provision and rural access are reported as weak, with rural and suburban regions alleged to have little or no endocrinologist access ⁹. This last claim is presented as an allegation in the source and is not confirmed.

Named commercial companies with verified market data were not present in the pack. Comparable examples are therefore limited. The named organizations in the pack are the IDF, which publishes prevalence data ¹²; WHO, which assesses insulin access ⁶; and the Endocrine Society, which is working on workforce supply and demand ¹³. These are data producers or policy actors, not market competitors.

Competitive pressure in the pack is mainly on the supply side: specialist demand is growing faster than the supply of specialists, and insulin supply depends on a small number of producers ⁶. A vendor blog that compares insulin prices ¹⁴ is not treated as evidence of competitive structure.

Concentration and market share cannot be assessed from the pack.

5Technology, operations and workforce

Verified evidence on digital health, telemedicine, continuous glucose monitoring and other diabetes technologies is not in the pack. Technology adoption, productivity effects and outcome gains cannot be assessed here. WHO's insulin access work covers insulin and associated devices as a supply issue ⁷, which is the only technology-related evidence retrieved.

Workforce supply is the central operational constraint. An estimated 8,000 endocrinologists are active in the United States, equal to about 41,460 people in the general population per endocrinologist ¹³. An earlier source gives an upper bound of fewer than 6,500 endocrinologists caring for patients with diabetes, thyroid disease and related conditions ¹⁰. The two counts are not reconciled, and the pack lists the range as unverified.

Pipeline evidence is mixed. Endocrinology fellowship positions increased by 78% over about 15 years, yet many positions are not filling ¹³. Filled fellowship positions are a main factor in future workforce supply ¹¹. Poor compensation is cited as a key driver of the shortage ¹⁰. Without intervention, a shortage of about 2,700 endocrinologists is projected ¹¹.

Operationally, delegation to primary care is the main adjustment reported ⁹. The pack includes no verified productivity or staffing-ratio data by setting.

• Active endocrinologists in the United States 8,000endocrinologists (approximate) Observed United States, Latest available data [13]

No official current US workforce statistic was verified.

6Regulation, standards, risk and sustainability

Jurisdiction matters. The pack contains WHO guidance on insulin access ⁶⁷, which is recommendatory and not binding on national governments. The pack contains no verified binding regulation for drug pricing, device approval, workforce licensing or reimbursement in the United States or elsewhere. Binding requirements therefore cannot be stated, and no proposed rules were retrieved.

Quality and safety indicators are absent. No verified data on HbA1c control, complication rates or safety events by provider type were retrieved. This is a material gap for any assessment of standards.

Privacy: this report uses aggregate population data only. It does not contain individual patient information and is not individual medical advice.

Equity is a major concern at the global level. Four in five adults with diabetes live in low and middle-income countries ³, and treatment coverage is lowest there ⁵. Equity indicators by income or ethnicity within high-income countries were not retrieved.

Operational and data risks include the shortage of specialists ¹³, uncertain insulin supply ⁶, and incomplete type 1 diabetes incidence data for most countries ⁴. Environmental and sustainability factors were not covered by the pack, so no claims are made here. Diabetes contributed to an estimated 3.4 million deaths ³.

Binding and voluntary instruments are distinguished where the pack allows. Jurisdictions outside the pack are not assessed.

7Challenges, opportunities and case examples

Major constraints are the diagnosis gap ³, treatment gap ⁵, insulin access barriers ⁶ and specialist workforce shortage ¹¹¹³. Affordability is a documented barrier, but current prices were not verified ⁶.

Opportunities in the pack include wider use of primary care for diabetes care, which is already happening in low and middle-income countries ⁹. Filling fellowship places could affect future supply ¹¹¹³. WHO proposes actions to promote universal insulin access ⁶, although the pack does not report measured results.

Case example 1: the Endocrine Society's supply and demand initiative responds to a fellowship recruitment gap in the United States ¹³. Its outcomes are not verified in the pack. Case example 2: WHO's report on insulin availability maps barriers and suggests actions ⁶. Implementation status is not reported. Case example 3: pediatric endocrinology shortages in several US states, where some states have fewer than 5 specialists ¹². These examples are attributable but not outcome-verified.

Comparable commercial case examples were limited in the pack, so this section relies on institutional examples.

8Outlook and strategic implications

Near term, the most defensible expectation is that demand continues to rise. The IDF forecast of about 853 million adults with diabetes ² and a rising prevalence ¹ point to more care need. This is a forecast, and the pack does not test alternative scenarios.

Medium term, specialist capacity is the binding constraint in the United States unless the fellowship pipeline and compensation issues are addressed ¹⁰¹¹¹³. A plausible scenario is wider delegation to primary care ⁹, but its quality effects are not verified. A second scenario depends on whether insulin supply and affordability improve ⁶.

Uncertainties include conflicting US workforce counts ¹⁰¹³, limited incidence data for type 1 diabetes ⁴, and the absence of verified quality, pricing and digital adoption indicators.

Implications: providers should track diagnosis and treatment gaps and plan for specialist shortages. Payers and policymakers should weigh access evidence against cost, and manufacturers and suppliers should note the supply concentration WHO describes ⁶. Researchers should prioritize quality, equity and cost data, which the pack shows to be missing.

Interpretive statements are labeled in the text. Confidence in scenarios is low to medium.

9Conclusion

The latest available evidence shows a large and growing diabetes population, substantial undiagnosed and untreated disease, and documented specialist workforce pressure in the United States ²³¹³. The most defensible takeaways are that demand is rising faster than specialist supply, that insulin access is a global equity issue ⁶, and that the market-level data needed for a full assessment are not yet available.

How this was built

Sources

1. 1

   11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates and projections

   IDF Diabetes Atlas authors (published in The Lancet Diabetes & Endocrinology) Peer-reviewed

   sciencedirect.com
2. 2

   Diabetes Facts and Figures

   International Diabetes Federation Industry association

   idf.org
3. 3

   IDF Diabetes Atlas global data and insights

   International Diabetes Federation Industry association

   diabetesatlas.org
4. 4

   Global type 1 diabetes prevalence, incidence, and mortality estimates

   IDF Atlas T1D Special Interest Group and T1D Index team Peer-reviewed

   diabetesresearchclinicalpractice.com
5. 5

   Diabetes fact sheet

   World Health Organization Regulator

   who.int
6. 6

   New WHO report maps barriers to insulin availability and suggests actions to promote universal access

   World Health Organization Regulator

7. 7

   Keeping the 100-year-old promise: making insulin access universal

   World Health Organization Regulator

   who.int
8. 8

   Population-based geographic access to endocrinologists in the United States

   Authors of PMC4672571 (National Center for Biotechnology Information) Peer-reviewed

   ncbi.nlm.nih.gov
9. 9

   The United States Endocrinology Workforce: A Supply-Demand Mismatch

   Authors of the ResearchGate-hosted article Peer-reviewed

   researchgate.net
10. 10

    Growing Need, but Shrinking Workforce: Endocrinology

    Medscape News report

    medscape.com
11. 11

    Trends in the Endocrinology Fellowship Recruitment: Reasons for Concern and Possible Interventions

    Journal of Clinical Endocrinology & Metabolism authors (PMC7150610) Peer-reviewed

    ncbi.nlm.nih.gov
12. 12

    Understanding the Decline of Pediatric Endocrinology Workforce and the Path Forward

    Authors of ScienceDirect review article Peer-reviewed

    sciencedirect.com
13. 13

    Endocrinology Workforce Supply and Demand: Mind the Gap

    Endocrine Society (Endocrine News) Industry association

    endocrinenews.endocrine.org
14. 14

    Insulin statistics: costs, usage and diabetes rates

    SingleCare (vendor blog) Vendor report

    singlecare.com